$EAT

Brinker International’s (NYSE:EAT) Q2 CY2026 Earnings Results: Revenue In Line With Expectations, Full

Brinker International (NYSE:EAT) reported Q2 CY2026 revenue of $1.54 billion, up 5.1% year on year and in line with Wall Street expectations. Full-year revenue guidance is $6.21 billion at the midpoint, 1.1% above analysts’ estimates. Non-GAAP EPS was $3.07, 0.5% below consensus, and the stock rose 2.3% to $226.50 after the release.

Original reporting
Published Aug 12, 2026, 11:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Brinker International’s (NYSE:EAT) Q2 CY2026 Earnings Results: Revenue In Line With Expectations, Full — source image
Decision brief

The 30-second read

$EATNeutralMed
01

Why it matters

Q2 revenue met expectations and full-year revenue guidance slightly beat, but non-GAAP EPS was 0.5% below consensus and EBITDA missed. Same-store sales rose 5.1% YoY, a deceleration from prior levels, making the next few quarters’ reacceleration a key swing factor.

02

Market read

This is a company-specific earnings/guidance update with enough detail (revenue, guidance midpoint, EPS miss, same-store deceleration) to adjust near-term estimates and positioning.

03

What to watch

The article flags full-year revenue guidance slightly above estimates but does not quantify cost pressures or margin drivers, so traders should verify whether the EPS miss reflects temporary items or structural margin pressure.

Relevance 8/10Novelty 7/10Timing: post-earnings, immediately after the Q2 report

Background

Brinker International operates Chili's, Maggiano's Little Italy, and It's Just Wings, and the article frames Q2 performance around revenue, same-store sales, and restaurant count stability.

Company-level read

Ticker impact

$EATNeutralMedium confidence
Context

Brinker reported Q2 CY2026 revenue of $1.54B, met expectations, and guided full-year revenue to $6.21B midpoint.

Expected impact

Near-term bias modestly positive on revenue guidance credibility, but upside may be capped by EPS/EBITDA misses and same-store deceleration.

Evidence & confidence

The article provides concrete Q2 results (revenue in line), full-year revenue guidance vs estimates, and profit shortfall vs consensus, plus a same-day reaction (+2.3%). Traders can reassess valuation and forward estimates based on these specific datapoints.

Market effects

Restaurant peers may see read-through on Chili's same-store momentum and whether demand is reaccelerating after a deceleration.

No specific regional demand or macro linkage is provided in the article.

No global supply-chain or international exposure details are disclosed.

Counterpoint

The print may be less bullish than the stock pop implies because non-GAAP EPS and EBITDA missed consensus, and same-store sales decelerated to 5.1% from a higher historical pace.

Key entities

  • Brinker International

    Reported Q2 CY2026 revenue and provided full-year revenue and EPS-related guidance versus consensus.

  • Kevin Hochman

    CEO who commented that Q4 2026 completes five consecutive years of Chili's same-store sales growth.

Related articles

$EATHighAI 9/10

BRINKER INTERNATIONAL, INC (EAT): Results of Operations and Financial Condition

BRINKER INTERNATIONAL, INC (EAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 fy26q4ex991-earningsrelease.htm EX-99.1 Document Exhibit 99.1 BRINKER INTERNATIONAL REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2026 RESULTS AND PROVIDES FISCAL 2027 GUIDANCE DALLAS (August 12, 2026) – Brinker International, Inc. (NYSE: EAT) today announced its financia

$EATMedAI 8/10

Brinker International Sees Strong Growth In FY27 - Update

Brinker International (EAT) reported fourth-quarter results and issued full-year 2027 guidance. It projects adjusted EPS of $12.60 to $13.40 on total revenue of $6.15 billion to $6.27 billion, up from prior $10.60 to $10.85 EPS and $5.78 billion to $5.82 billion revenue. The company attributed the change to an added operating week, estimating about +2.0% revenue and +$0.70 EPS.

$EATMed

Why Brinker International (EAT) Stock Is Up Today

Brinker International (EAT) shares rose 6.8% in the afternoon after TD Cowen raised its price target to $192 from $170 and kept a Buy rating, citing confidence in Chili’s results. CEO Kevin Hochman said Chili’s has logged 20 straight quarters of comparable sales growth. The article notes Wall Street expects 21% earnings growth for 2026.

$CAVAMedAI 8/10

CAVA's Biggest Growth Driver Isn't Higher Prices

CAVA Group (NYSE:CAVA) gained 11.38% premarket after reporting Q2 diluted EPS of $0.19 on revenue of $368.4M, above consensus of $0.18 and $360.09M. Same-restaurant sales rose 9.0%, with 5.3% from guest traffic. Net income was $23.0M; adjusted EBITDA rose 30% to $54.7M. Restaurant margin fell to 25.7%. CAVA reaffirmed FY guidance: same-restaurant sales 4.5% to 6.5%, 75 to 77 net new restaurants, and adjusted EBITDA $181M to $191M.

$SMWBHighAI 8/10

Why is SimilarWeb stock surging today?

SimilarWeb (SMWB) shares rose about 13.7% in pre-open trading after the company reported Q2 2026 results above Wall Street expectations. Adjusted EPS was $0.06 vs $0.03 consensus, and revenue was $77.2M vs $75.5M. SimilarWeb raised full-year guidance and secured multi-year contracts totaling over $60M, while Northland Capital upgraded SMWB and doubled its price target to $10.

$APREMed

Aprea Therapeutics, Inc. (APRE): Results of Operations and Financial Condition

Aprea Therapeutics, Inc. (APRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 apre-20260812xex99d1.htm EX-99.1 ​ Exhibit 99.1 ​ Aprea Therapeutics Announces Second Quarter 2026 Financial Results ​ Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea p